Predicting clear cell subtype for kidney tumors from cross-sectional imaging using artificial intelligence.

H Haya Abusafieh (Department of Urology, Cleveland Clinic, Cleveland, OH) R Rikhil Seshadri (Department of Urology, Cleveland Clinic, Cleveland, OH) S Sahil Hasit Patel (Case Western Reserve University, Cleveland, OH) R Rishi Jonnalagadda (Department of Urology, Cleveland Clinic, Cleveland, OH) D Daniel Jevnikar (Cleveland Clinic, Cleveland, OH) S Salim Younis (Cleveland Clinic, Cleveland, OH) A Abdulrahman Al-Bayati (Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH) N Nicolas Soputro (Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH) J Jacob Michael Knorr (Department of Urology, Cleveland Clinic, Cleveland, OH) G Gagan Fervaha (Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH) M Michal Ozery-Flato M Michal Rosen-Zvi R Robert Abouassaly (Department of Urology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates) E Erick M. Remer (Department of Radiology, Cleveland Clinic, Cleveland, OH) N Nicholas Heller C Christopher Weight

Abstract

429 Background: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer in adults. The standard of care for localized RCC is partial or radical nephrectomy, or active surveillance for small tumors. The histologic tumor diagnosis may assist in shared decision making, but it is typically unknown prior to nephrectomy in the absence of a renal mass biopsy. Additionally, biopsies have imperfect diagnostic performance due to tumor heterogeneity. We sought to explore whether histopathologic diagnoses could be predicted based on radiomic data. In this study, we present the application of artificial intelligence (AI) to predict the clear cell subtype directly from imaging. Methods: We retrospectively reviewed patients who underwent nephrectomy and had a preoperative contrast-enhanced abdominal CT imaging available from 10/2009 to 7/2024 at a single large health system. A ResNet-50 architecture was fine-tuned to predict whether the tumor was ccRCC. 5-Fold cross-validation was used to obtain predictions for all patients. A second set of models was trained on the subset of patients with tumor sizes of 3cm to 7cm. The ensemble of 5 models was used to perform external validation on an independent dataset. DeLong’s tests were performed to compare AUC of the AI model and tumor size prediction model. Results: A total of 1,642 nephrectomy patients at the primary institution had available imaging and subtype classifications, of which 822 fell into the 3-7 cm cohort. For the whole cohort, the model achieved an AUC of 0.71, significantly outperforming the tumor size AUC of 0.54 (p = 6.6e-21). For the 3-7cm subset, the model achieved an AUC of 0.81, again significantly outperforming the tumor size AUC of 0.49 (p = 2.1e-26). For the external validation cohort, the model did significantly outperform tumor size with AUCs of 0.59 and 0.44 respectively (p = 0.009) on the 3-7 cm cohort. However, on the whole external validation cohort, the model did not significantly outperform tumor size. Conclusions: This study demonstrates that a computer-vision-based AI model is capable of predicting clear cell renal cell carcinoma from CT images in kidney cancer patients better than tumor size. This presents an alternative to biopsies for pre-surgical decision-making in patients whose treatment decision may be influenced by knowing their renal tumor subtype.

Article Details

Volume / Issue Vol. 44, Issue 7_suppl
Published March 01, 2026
Pages 429-429
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (16)

H

Haya Abusafieh

Department of Urology, Cleveland Clinic, Cleveland, OH

R

Rikhil Seshadri

Department of Urology, Cleveland Clinic, Cleveland, OH

S

Sahil Hasit Patel

Case Western Reserve University, Cleveland, OH

R

Rishi Jonnalagadda

Department of Urology, Cleveland Clinic, Cleveland, OH

D

Daniel Jevnikar

Cleveland Clinic, Cleveland, OH

S

Salim Younis

Cleveland Clinic, Cleveland, OH

A

Abdulrahman Al-Bayati

Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH

N

Nicolas Soputro

Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH

J

Jacob Michael Knorr

Department of Urology, Cleveland Clinic, Cleveland, OH

G

Gagan Fervaha

Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH

M

Michal Ozery-Flato

M

Michal Rosen-Zvi

R

Robert Abouassaly

Department of Urology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates

E

Erick M. Remer

Department of Radiology, Cleveland Clinic, Cleveland, OH

N

Nicholas Heller

C

Christopher Weight